119 related articles for article (PubMed ID: 37068706)
1. Pogostone attenuates osteolysis in breast cancer by inhibiting the NF-kB and JNK signaling pathways of osteoclast.
Zheng T; Lin Z; Jiang G; Chen H; Yang Y; Zeng X
Life Sci; 2023 Sep; 328():121611. PubMed ID: 37068706
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways.
Yin Z; Zhu W; Wu Q; Zhang Q; Guo S; Liu T; Li S; Chen X; Peng D; Ouyang Z
Eur J Pharmacol; 2019 Sep; 859():172550. PubMed ID: 31323222
[TBL] [Abstract][Full Text] [Related]
3. Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway.
Li Y; Zhuang Q; Tao L; Zheng K; Chen S; Yang Y; Feng C; Wang Z; Shi H; Shi J; Fang Y; Xiao L; Geng D; Wang Z
Cell Prolif; 2022 Oct; 55(10):e13291. PubMed ID: 35708050
[TBL] [Abstract][Full Text] [Related]
4. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
5. Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation.
Li J; Feng W; Lu H; Wei Y; Ma S; Wei L; Liu Q; Zhao J; Wei Q; Yao J
J Cell Physiol; 2019 Aug; 234(8):12663-12675. PubMed ID: 30536376
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment.
Xu Q; Zhan P; Li X; Mo F; Xu H; Liu Y; Lai Q; Zhang B; Dai M; Liu X
J Cell Mol Med; 2021 Nov; 25(21):10126-10139. PubMed ID: 34651433
[TBL] [Abstract][Full Text] [Related]
7. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhai ZJ; Li HW; Liu GW; Qu XH; Tian B; Yan W; Lin Z; Tang TT; Qin A; Dai KR
Br J Pharmacol; 2014 Feb; 171(3):663-75. PubMed ID: 24125472
[TBL] [Abstract][Full Text] [Related]
8. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
9. Trimethylamine-N-Oxide Promotes Osteoclast Differentiation and Bone Loss via Activating ROS-Dependent NF-κB Signaling Pathway.
Wang N; Hao Y; Fu L
Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235607
[TBL] [Abstract][Full Text] [Related]
10. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of melatonin on titanium particle-induced inflammatory bone resorption and osteoclastogenesis via suppression of NF-κB signaling.
Ping Z; Wang Z; Shi J; Wang L; Guo X; Zhou W; Hu X; Wu X; Liu Y; Zhang W; Yang H; Xu Y; Gu Y; Geng D
Acta Biomater; 2017 Oct; 62():362-371. PubMed ID: 28867647
[TBL] [Abstract][Full Text] [Related]
12. Abietic acid attenuates RANKL induced osteoclastogenesis and inflammation associated osteolysis by inhibiting the NF-KB and MAPK signaling.
Thummuri D; Guntuku L; Challa VS; Ramavat RN; Naidu VGM
J Cell Physiol; 2018 Jan; 234(1):443-453. PubMed ID: 29932225
[TBL] [Abstract][Full Text] [Related]
13. Geraniin suppresses RANKL-induced osteoclastogenesis in vitro and ameliorates wear particle-induced osteolysis in mouse model.
Xiao F; Zhai Z; Jiang C; Liu X; Li H; Qu X; Ouyang Z; Fan Q; Tang T; Qin A; Gu D
Exp Cell Res; 2015 Jan; 330(1):91-101. PubMed ID: 25016282
[TBL] [Abstract][Full Text] [Related]
14. Punicalin Attenuates Breast Cancer-Associated Osteolysis by Inhibiting the NF-κB Signaling Pathway of Osteoclasts.
Li T; Jiang G; Hu X; Yang D; Tan T; Gao Z; Chen Z; Xiang C; Li S; Ouyang Z; Guo X
Front Pharmacol; 2021; 12():789552. PubMed ID: 34867423
[No Abstract] [Full Text] [Related]
15. Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss.
Han SY; Kim YK
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946658
[TBL] [Abstract][Full Text] [Related]
16. Dehydrocostus lactone attenuates osteoclastogenesis and osteoclast-induced bone loss by modulating NF-κB signalling pathway.
Hu B; Wu F; Shi Z; He B; Zhao X; Wu H; Yan S
J Cell Mol Med; 2019 Aug; 23(8):5762-5770. PubMed ID: 31225720
[TBL] [Abstract][Full Text] [Related]
17. Icariin abrogates osteoclast formation through the regulation of the RANKL-mediated TRAF6/NF-κB/ERK signaling pathway in Raw264.7 cells.
Kim B; Lee KY; Park B
Phytomedicine; 2018 Dec; 51():181-190. PubMed ID: 30466615
[TBL] [Abstract][Full Text] [Related]
18. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis.
Hsieh TP; Sheu SY; Sun JS; Chen MH
Phytomedicine; 2011 Jan; 18(2-3):176-85. PubMed ID: 20554188
[TBL] [Abstract][Full Text] [Related]
19. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
20. Surfactin suppresses osteoclastogenesis via the NF-κB signaling pathway, promotes osteogenic differentiation in vitro, and inhibits oestrogen deficiency-induced bone loss in vivo.
Kuang Z; Yang X; Cao Z; Li Y; Hu J; Hong X; Li B; Wu C; Qi Q; Liu X; Dai M
Int Immunopharmacol; 2023 Apr; 117():109884. PubMed ID: 36805201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
